evaluation of the effect of co-administration of irak inhibitor and pioglitazone on ppar-γ, glut-4, tnf-α, and leptin genes expression in adipose tissue of insulin-resistant mice

Background: the worldwide prevalence of diabetes is increasing. diabetes is a complex disease that results from impaired secretion of insulin or insulin resistance. in adipose tissue, insulin increases glucose uptake by stimulating the transfer of glucose transporter type 4 (glut-4) to the plasma membrane. in this study, the effect of irak inhibitor (iraki) and pioglitazone on genes expression in adipose tissue of insulin resistant mice was evaluated. methods: mice were randomly divided into 6 groups (n= 8 each), five groups of which were fed a high-fat diet and one group received a normal diet for 12 weeks. the treatment with pioglitazone and iraki was performed for 2 weeks. at the end of the study, the animals were sacrificed and the adipose tissue and blood samples were collected. the expression of glut4, tnf-α, peroxisome proliferator-activated receptor gamma (pparγ), and lepin were determined by real-time pcr in the adipose tissue. the malondialdehyde (mda) level and total antioxidant capacity (tac) in serum were measured. results were analyzed by spss 22. results: the data showed that the combination of iraki and pioglitazone increased pparγ expression, leptin and tac levels in serum, and reduced tnf-α expression and mda levels. the glut4 expression in adipose tissue was not significant between studied groups. pioglitazone and iraki improved insulin function by inhibiting inflammation signaling. conclusion: according to the results of this study, iraki may be an appropriate target for inhibiting inflammation and related disorders, including insulin resistance.